Histogen announced the publication of data on HST 004, its naturally-derived material for spinal disc repair.
The company’s cell conditioned media has been shown to stimulate stem cells in vivo. The material expresses stem cell-associated proteins and has the potential to reduce inflammation and stimulate autologous intravertebral disc (IVD) cells, which may lead to the repair of IVD matrix.
In a spinal disc study, HST 004 reversed inflammation and protease activity and stimulated aggrecan secretion in the thrombin-induced rabbit ex vivo model. In vivo studies in the rabbit model showed that, in 4 weeks post treatment with HST 004, disc height increased as compared to control, while MRI analysis demonstrated regeneration of disc tissue.
“We are encouraged by this data on HST 004 and we look forward to generating additional pre-clinical data later this year in anticipation of filing an investigational new drug application on spinal disc repair in 2021,” said Richard Pascoe, Chairman and CEO of Histogen.
Earlier this year, Histogen entered into a definitive merger agreement with Conatus Pharmaceuticals. The combined company will retain the Histogen name and on advancement of its patented technology for dermatological and orthopedic indications.
The merger is expected to close by the end of 2Q20.
Histogen announced the publication of data on HST 004, its naturally-derived material for spinal disc repair.
The company's cell conditioned media has been shown to stimulate stem cells in vivo. The material expresses stem cell-associated proteins and has the potential to reduce inflammation and stimulate autologous intravertebral disc...
Histogen announced the publication of data on HST 004, its naturally-derived material for spinal disc repair.
The company’s cell conditioned media has been shown to stimulate stem cells in vivo. The material expresses stem cell-associated proteins and has the potential to reduce inflammation and stimulate autologous intravertebral disc (IVD) cells, which may lead to the repair of IVD matrix.
In a spinal disc study, HST 004 reversed inflammation and protease activity and stimulated aggrecan secretion in the thrombin-induced rabbit ex vivo model. In vivo studies in the rabbit model showed that, in 4 weeks post treatment with HST 004, disc height increased as compared to control, while MRI analysis demonstrated regeneration of disc tissue.
“We are encouraged by this data on HST 004 and we look forward to generating additional pre-clinical data later this year in anticipation of filing an investigational new drug application on spinal disc repair in 2021,” said Richard Pascoe, Chairman and CEO of Histogen.
Earlier this year, Histogen entered into a definitive merger agreement with Conatus Pharmaceuticals. The combined company will retain the Histogen name and on advancement of its patented technology for dermatological and orthopedic indications.
The merger is expected to close by the end of 2Q20.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
